Ketoconazole (KET) is active to control dandruff and seborrhoeic dermatitis. Objective assessments comparing the 1% and 2% shampoo formulations are scant. This open, randomized parallel-group trial was carried out to differentiate the effectiveness of KET 1% and 2% in severe dandruff and seborrhoeic dermatitis. A total of 66 patients with severe dandruff or seborrhoeic dermatitis were randomized to each of the two groups. A 2-week run-in phase was followed by a 4-week treatment phase, in turn followed by a 4-week follow-up. The efficacy of treatments was evaluated by combining squamometry X, Malassezia spp. counts and clinical assessments. After 2 and 4 weeks of treatment, KET 2% was significantly superior over KET 1% (p < 0.001) for decreasing both in flakiness and Malassezia density from baseline. The same trend was observed in the mean change from baseline in the overall dandruff severity score. Only 6 mild adverse events were reported. During follow-up KET 2% showed a trend to fewer relapses than KET 1%. KET 2% had superior efficacy compared to KET 1% in the treatment of severe dandruff and scalp seborrhoeic dermatitis. Biometrological evaluations were correlated with the clinical improvements and therefore useful to incorporate in future dandruff studies.

Keywords:
Dandruff, Ketoconazole, Malassezia spp., Seborrhoeic dermatitis, Squamometry
1.
Shuster S: The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984;111:235–242.
2.
Faergemann J: Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1:75–80.
3.
Piérard-Franchimont C, Hermanns JF, Degreef H, Piérard GE: From axioms to new insights into dandruff. Dermatology 2000;200:93–98.
4.
Piérard-Franchimont C, Willemaers V, Fraiture AL, Piérard GE: Squamometry in seborrheic dermatitis. Int J Dermatol 1999;38:712–715.
5.
Faergemann J: Propylene glycol in the treatment of seborrheic dermatitis of the scalp: A double-blind study. Cutis 1988;42:69–71.
6.
Ford GP, Farr PM, Ive FA, Shuster S: The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984;111:603–607.
7.
Skinner RB, Noah PW, Taylor RM, Zanolli MD, West S, Gwin JD, Rosenberg EW: Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985;2:852–857.
8.
Cauwenbergh G, De Doncker P, Schrooten P, Degreef H: Treatment of dandruff with a 2% ketoconazole scalp gel: A double-blind, placebo-controlled study. Int J Dermatol 1986;25:541.
9.
Berger R, Mills OH, Johnson RW, Jones EL, Mrusck S: Double-blind, placebo-controlled trial of ketoconazole 2% shampoo in the treatment of moderate to severe dandruff. Adv Ther 1990;7:247–256.
10.
Faergemann J: Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. Acta Derm Venereol 1990;70:171–172.
11.
Danby FW, Maddin WS, Margesson LJ, Rosenthal D: A randomised double-blind study of ketoconazole 2% shampoo versus selenium sulphide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993;29:1008–1012.
12.
Shuttleworth D, Squire RA, Boorman GC, Goode K: Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%; Nizoral) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998;9:157–162.
13.
Stratigos ID, Antoniou CH, Katambas A, Böhler K, Fritsch P, Schmölz A, Michaelidis D, De Beule K: Ketoconazole 2% cream versus 1% hydrocortisone cream in the treatment of seborrheic dermatitis: A double-blind comparative study. J Am Acad Dermatol 1988;19:850–853.
14.
Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y: Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology 1992;184:275–280.
15.
Pari T, Pulimood S, Jacob M, George S, Jeyaseehan L, Thomas K: Randomised double-blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1998;10:89–90.
16.
Vanít Veen AJ, Prevoo RLMA, Velders AJ, Jagtman BA, Van Niel JCG, Stolz E: Betamethasone-17-valerate compared with ketoconazole for topical treatment of seborrhoeic dermatitis of the scalp in adults: Results of a Dutch multicentre study. J Dermatol Treat 1998;9:239–245.
17.
Piérard-Franchimont C, Arrese JE, Durupt G, Ries G, Cauwenbergh G, Piérard GE: Correlation between Malassezia spp. load and dandruff severity. J Mycol Med 1998;8:83–86.
18.
Piérard GE: EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: Evaluation by stratum corneum strippings. Skin Res Technol 1996;2:3–11.
19.
Arrese JE, Piérard-Franchimont C, De Doncker P, Heremans A, Cauwenbergh G, Piérard G: Effect of ketoconazole-medicated shampoos on squamometry and Malassezia ovalis load in pityriasis capitis. Cutis 1996;58:235–237.
20.
Piérard-Franchimont C, De Doncker P, Wallace R, Cauwenbergh G, Piérard GE: Ketoconazole shampoo: Effect of long-term use in androgenic alopecia. Dermatology 1998;196:474–477.
21.
Piérard-Franchimont C, Henry F, Piérard GE: The SACD method and the XLRS squamometry tests revisited. Int J Cosmet Sci 2000;22:437–446.
22.
Piérard GE: EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998;10:1–11.
23.
Piérard-Franchimont C, Arrese JE, Piérard GE: Immunohistochemical aspects of the link between Malassezia ovalis and seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1995;4:14–19.
24.
Kesavan S, Walters CE, Holland KT, Ingham E: The effects of Malassezia on proinflammatory cytokine production by human peripheral blood mononuclear cells in vitro. Med Mycol 1998;36:97–106.
25.
Pearry ME, Sharpe GR: Seborrhoeic dermatitis is not caused by an altered immunoresponse to Malassezia yeast. Br J Dermatol 1998;139:254–263.
26.
Bergbrant I-M, Andersson B, Faergemann J: Cell-mediated immunity to Pityrosporum ovale in patients with seborrhoeic dermatitis and pityriais versicolor. Clin Exp Dermatol 1999;24:402–406.
27.
Janssen PA, Van den Bossche H, Van Wauwe JP, Cauwenbergh GF, Degreef HJ: The role of cytochrome P-450 in dermatology. Int J Dermatol 1989;28:493–496.
28.
Baroni A, Ruocco V, De Paolis P, Cicatiello L, Esumi, Tufano MA: Ketoconazole inhibits lipopolysaccharide-induced activation of the nitric oxide synthase gene in the murine macrophage cell line J774. Arch Dermatol Res 1999;291:54–58.
29.
Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PAJ: The anti-inflammatory effects of ketoconazole. J Am Acad Dermatol 1991;25:257–261.
30.
Rico AC, Lopez GH, Munoz LH, Bejarano CV: Evaluation del efecto antiinflamatorio de ketoconazole cream. Invest Med Int 1991;18:181–187.
31.
Yoshimura T, Kudoh K, Aiba S, Tagami H: Antiinflammatory effects of ketoconazole for the inflammation induced on the skin of hairless guinea-pigs by repeated applications of heat-killed spores of M. furfur: A comparative study with hydrocortisone 17-butyrate. J Dermatol Treat 1995;6:113–116.
32.
Roosen T, Schell BJ, Orengo I: Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997;36:788–792.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.